Current Month 2006
Article Features
  Study Suggests Drug For Chemotherapy-Induced Anemia Can Be Effectively Administered Tri-Weekly
Some Benign Breast Lesions Could Be Dangerous
New Test to Detect Rare Protein in Blood May Aid in Earlier Breast Cancer Diagnosis
Patients Want to Know Results of Their Clinical Trials
Study Finds Emotional Benefits from Participation in Computer Support Groups
Cost-Effectiveness of Preventive Strategies for Women with Breast Cancer Gene
Estrogen-Progestin Menopausal Hormone Therapy and Risk of Lobular and Tubular Breast Cancer
Gene Expression Profiling Identifies Certain High-Risk Breast Cancer
Genetic Testing Does Not Detect All Cancer-Associated Mutations in Certain Genes
Ginkgo Biloba Extract May Have Anti-Cancer Properties
High Risk of Breast Cancer Associated with Genetic Variation in Leptin and its Receptor
Korean Breast Cancer Patterns Reflect Those of Western Countries
New Studies to Focus on Molecular Markers and Obesity in High Risk Women
Mammography Use Among Older Breast Cancer Survivors
Non-BRCA Hereditary Breast Cancer Linked to New Cancers
Women Who Choose Preventive Mastectomy Are Satisfied With Their Decisions
Disclosing Study Outcomes to Participants May Backfire
Aggressive Subtype of Breast Cancer Displays “Misbehavior” of X Chromosomes

New Strategy to Study Disease Reveals Insight into Cancer Treatment

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets. What's more, the scientists' study, published in the journal Science, identifies a simple method to further understand the complex mechanisms that underlie cancer as well as other diseases and may provide an easy model to screen for new cancer drugs.

"Our study reveals a new way to study proteins in live cells, in this case, a tyrosine kinase implicated in causing cancer," says the study's lead author, Philip A. Cole, M.D., Ph.D., director of the Department of Pharmacology and Molecular Sciences at The Johns Hopkins University School of Medicine. "This approach helped identify potentially important therapeutic targets and in the future may provide a method to easily screen cancer treatments."

In the study, Cole and his colleagues examined the tyrosine kinase Src (pronounced SARK), a clinically important cancer protein that scientists have heavily studied but do not completely understand. The Johns Hopkins researchers developed a special mutated version of the Src protein and incorporated it into live animal cells. The mutated version was inactive but contained an "ignition switch" that would turn it back on. They determined that the small molecule, imidazole, could act as the key. Imidazole fit into a pocket in the mutated structure of the Src protein, which mended the structure and reinstated Src's activity. Removal of imidazole quickly shut the protein off again.

Read More of the Main Article

Visit the Ezine

Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon